GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice
Open accessThe DOI matches its Crossref record; 45 of the 47 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat type 2 diabetes, and transient GLP-1 administration improved cardiac function in humans after acute myocardial infarction (MI) and percutaneous revascularization. However, the consequences of GLP-1R activation before ischemic myocardial injury remain unclear. RESEARCH DESIGN AND METHODS: We assessed the pathophysiology and outcome of coronary artery occlusion in normal and diabetic mice pretreated with the GLP-1R agonist liraglutide. RESULTS: Male C57BL/6 mice were treated twice daily for 7 days with liraglutide or saline followed by induction of MI. Survival was significantly higher in liraglutide-treated mice. Liraglutide reduced cardiac rupture (12 of 60 versus 46 of 60; P = 0.0001) and infarct size (21 ± 2% versus 29 ± 3%, P = 0.02) and improved cardiac output (12.4 ± 0.6 versus 9.7 ± 0.6 ml/min; P = 0.002). Liraglutide also modulated the expression and activity of cardioprotective genes in the mouse heart, including Akt, GSK3β, PPARβ-δ, Nrf-2, and HO-1. The effects of liraglutide on survival were independent of weight loss. Moreover, liraglutide conferred cardioprotection and survival advantages over metformin, despite equivalent glycemic control, in diabetic mice with experimental MI. The cardioprotective effects of liraglutide remained detectable 4 days after cessation of therapy and may be partly direct, because liraglutide increased cyclic AMP formation and reduced the extent of caspase-3 activation in cardiomyocytes in a GLP-1R–dependent manner in vitro. CONCLUSIONS: These findings demonstrate that GLP-1R activation engages prosurvival pathways in the normal and diabetic mouse heart, leading to improved outcomes and enhanced survival after MI in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“These agents exert their anti-atherosclerotic effects through various mechanisms, including by improving blood lipid profiles,444 preserving endothelial integrity and regulating endothelial function,445 as well as modulating inflammatory processes.70”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [445]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 4×
“Glucagon-like peptide-1 (GLP-1), a member of the proglucagon-derived peptide family (2), exerts favorable actions on cardiovascular function in both preclinical and clinical studies.”
BackgroundInfluentialSelf-citationRegulation of cardiac hypertrophy by intracellular signalling pathways
Heineke, J., & Molkentin, J. D. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1983 · Cited by 1,866 · cited 1×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
Ban, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 3×
“The GLP-1 metabolite, GLP-1, also exerts cardioprotective actions when administered postischemia (3,16), further highlighting the complexity of different GLP-1–related peptides on the ischemic heart.”
BackgroundSelf-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Nikolaidis, L. A., Mankad, S., Sokos, G. G., Miske, G., Shah, A., Elahi, D., & Shannon, R. P. (2004) · Circulation · doi:10.1161/01.cir.0000120505.91348.58 · Cited by 901 · cited 3×
“A pilot study of GLP-1 administration for 72 h in human subjects with left ventricular (LV) dysfunction after myocardial injury and angioplasty demonstrated reduced hospital stay and improved global and regional LV wall motion scores, benefits that remained detectable even several weeks after hospital discharge (14).”
BackgroundResultGlucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
ResultSelf-citationHeymans, S., Luttun, A., Nuyens, D., Theilmeier, G., Creemers, E., Moons, L., Dyspersin, G. D., Cleutjens, J. P. M., Shipley, M., Angellilo, A., et al. (1999) · Nature Medicine · doi:10.1038/13459 · Cited by 794 · cited 2×
“* ** ** Untreated Liraglutide EX(9-39) Liraglutide +EX(9-39) Forskolin 0 10 20 30 40 50 60”
BackgroundSokos, G. G., Nikolaidis, L. A., Mankad, S., Elahi, D., & Shannon, R. P. (2006) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2006.08.211 · Cited by 656 · cited 2×
“Similarly, a 5-week course of GLP-1 infusion improved parameters of LV function, functional status, and quality of life in both diabetic and nondiabetic subjects with congestive heart failure (15).”
BackgroundGlucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion Injury
Bose, A. K., Mocanu, M. M., Carr, R. D., Brand, C. L., & Yellon, D. M. (2005) · Diabetes · doi:10.2337/diabetes.54.1.146 · Cited by 638
Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Self-citation
Cited by
Items 301–400 of 592
Tibble, C., Cavaiola, T. S., & Henry, R. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.13.20 · Cited by 24
PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury
Gao, H., Kiesewetter, D. O., Zhang, X., Huang, X., Guo, N., Lang, L., Hida, N., Wang, H., Wang, H., Cao, F., et al. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.109413 · Cited by 27
“However, it has been widely accepted that GLP-1 exerts a direct cytoprotective effect via inhibition of apoptosis directly in target cells expressing GLP-1R through both cyclic adenosine monophosphate and phosphoinositide 3-kinase pathways (10,11).”
BackgroundInfluentialMay, A. T., Crowe, M. S., Blakeney, B. A., Mahavadi, S., Wang, H., Grider, J. R., & Murthy, K. S. (2018) · Peptides · doi:10.1016/j.peptides.2018.11.007 · Cited by 31
“In cardiovascular tissue, activation of GLP-1R by GLP-1 is thought to induce cardioprotective effects via activation of anti-apoptotic mechanisms in cardiomyocytes [15].”
BackgroundAguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip
Luconi, M., Cantini, G., Ceriello, A., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.126 · Cited by 24
Trombara, F., Cosentino, N., Bonomi, A., Ludergnani, M., Poggio, P., Gionti, L., Baviera, M., Colacioppo, P., Roncaglioni, M. C., Leoni, O., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01758-y · Cited by 25
“[30] showed, in an experimental model, that liraglutide administration for 7 days before AMI induction reduces infarct size and improves survival by engaging pro-survival pathways in cardiomyocyte.”
BackgroundBenefit-Risk Assessment of Exenatide in the Therapy of Type 2 Diabetes Mellitus
Gallwitz, B. (2010) · Drug Safety · doi:10.2165/11319130-000000000-00000 · Cited by 24
van den Brom, C. E., Bulte, C. S. E., Loer, S. A., Bouwman, R. A., & Boer, C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-42 · Cited by 25
“Liraglutide T2DM, infarction [133,134] Reduction glucose Hypoglycaemia”
BackgroundSun, Z., Tong, G., Kim, T. H., Ma, N., Niu, G., Cao, F., & Chen, X. S. (2014) · Theranostics · doi:10.7150/thno.10226 · Cited by 24
“Recently, GLP-1 and its analogs were brought under the spotlight for their potent therapeutic potential for ischemic heart disease [4, 8], namely myocardial ischemia/reperfusion injury [8] and chronic heart failure secondary to myocardial infarction (MI) [6].”
BackgroundThe Incretin Axis in Cardiovascular Disease
Plutzky, J. (2011) · Circulation · doi:10.1161/circulationaha.111.064139 · Cited by 27
Shchendrygina, A., Rakisheva, A., Giverts, I., Rustamova, Y., & Soloveva, A. E. (2024) · Cardiac failure review · doi:10.15420/cfr.2024.05 · Cited by 24
“33 34–37 Several small studies reported that liraglutide significantly improved LV diastolic function in T2D patients compared with either placebo or other glucose-lowering agents, which was also associated with improvements in endothelial function and antioxidant and anti-inflammatory activity.”
BackgroundYounce, C. W., Niu, J., Ayala, J., Burmeister, M. A., Smith, L. H., Kolattukudy, P. E., & Ayala, J. E. (2014) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2014.08.022 · Cited by 26
“Three month old male MHC-MCP1 mice were implanted with osmotic minipumps delivering PBS or Ex4 (24 nmol · kg−1 · day−1 (100 μg · kg−1 · day−1), a dose chosen based on therapeutic− efficacy in previous mouse experiments [7]) for 8 weeks andwere compared to FVB/Nmice receiving PBS (WT).”
Darwesh, A. M., El-Azab, M. F., Abogresha, N. M., El-Sayed, N. M., & Moustafa, Y. M. (2017) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000557 · Cited by 23
Fang, J., Tang, Y., Cheng, X. W., Wang, L., Cai, C., Zhang, X., Liu, S., & Li, P. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.03.012 · Cited by 25
Mohabeer, A. L., Kroetsch, J. T., McFadden, M. J., Khosraviani, N., Broekelmann, T. J., Hou, G., Zhang, H., Zhou, Y., Wang, M., Gramolini, A. O., et al. (2021) · Matrix Biology Plus · doi:10.1016/j.mbplus.2021.100085 · Cited by 23
“Heart function parameters were determined as previously described in detail [17].”
MethodSelf-citationBaek, S. H., Kim, S. H., Kim, J. W., Kim, Y. J., Lee, K., & Na, K. R. (2015) · Trials · doi:10.1186/s13063-015-0772-4 · Cited by 21
“However, in addition to the glucose-lowering effects of DPP4 inhibitors, tissueprotective effects of DPP4 inhibition have been also demonstrated [19–23].”
The Impact of Current and Novel anti-diabetic Therapies On Cardiovascular Risk
Ussher, J. R., Sutendra, G., & Jaswal, J. S. (2012) · Future Cardiology · doi:10.2217/fca.12.68 · Cited by 21
“Native GLP-1 and exendin-4, but not liraglutide, also demonstrated protection against ex vivo I/R injury in isolated mouse Langendorff perfused hearts [78,79].”
BackgroundWright, E. J., Hodson, N. W., Sherratt, M. J., Kassem, M. S., Lewis, A. L., Wallrapp, C., Malik, N., & Holt, C. M. (2016) · Stem Cells International · doi:10.1155/2016/7357096 · Cited by 21
“Administration of theGLP-1 analogue Liraglutide similarly showed cardioprotective benefits following MI, reducing caspase-3 activation via the GLP-1R in a mouse model [14].”
BackgroundLiraglutide attenuates partial warm ischemia-reperfusion injury in rat livers
Abdelsameea, A. A., Abbas, N. A. T., & Raouf, S. M. A.-E. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1330-7 · Cited by 23
Brown, S. B., Libonati, J. R., Selak, M. A., Shannon, R. P., & Simmons, R. A. (2010) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-010-6242-z · Cited by 20
Sanon, S., Patel, R., Eshelbrenner, C., Sanon, V. P., Alhaddad, M., OLIVEROS, R. A., Pham, S. V., & CHILTON, R. J. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.035 · Cited by 21
Kitahara, Y., Miura, K., Yasuda, R., Kawanabe, H., Ogawa, S., & Eto, Y. (2011) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.34.671 · Cited by 21
Shirakawa, J., Okuyama, T., Kyohara, M., Yoshida, E., Togashi, Y., Tajima, K., Yamazaki, S., Kaji, M., Koganei, M., Sasaki, H., et al. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0138-4 · Cited by 23
“The improvement of cardiac function after myocardial infarction through a combination of DPP-4 inhibition and G-CSF administration has been reported, and liraglutide was able to confer cardioprotection and a survival advantage after myocardial infarction [38, 39].”
BackgroundGiblett, J. P., Axell, R. G., White, P. A., Clarke, S. J., McCormick, L., Read, P. A., Reinhold, J., Brown, A. J., O’Sullivan, M., West, N. E. J., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0416-3 · Cited by 20
“Animal studies have shown that phosphoinositol-3 kinase (PI3K) and Akt are consistently activated during treatment with GLP-1 [11, 18, 26].”
BackgroundKim, G. S., Park, J. H., & Won, J. C. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.2.106 · Cited by 20
Pan, X., Xu, S., Li, J., & Tong, N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.599355 · Cited by 21
“The cardioprotective actions of native GLP-1 demonstrated in human and animal studies, perfused ischemic hearts and cardiomyocyte cultures are associated with GLP-1R-dependent induction of a cardioprotective gene and protein expression profile, which have been well reviewed elsewhere (40, 53).”
BackgroundConsensus guidelines, algorithms and care of the individual patient with type 2 diabetes
Nolan, J. J. (2010) · Diabetologia · doi:10.1007/s00125-010-1767-z · Cited by 20
Iwasa, M., Yamada, Y., Kobayashi, H., Yasuda, S., Kawamura, I., Sumi, S., Shiraki, T., Yamaki, T., Ushikoshi, H., Hattori, A., et al. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01357.x · Cited by 21
DPP4 Deficiency Preserved Cardiac Function in Abdominal Aortic Banding Rats
Ku, H.-C., & Su, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085634 · Cited by 23
“Besides glucose homeostasis controlling, GLP-1 increased AKT, ERK, and eNOS signaling to activate survival pathway, which were associated with the outcome improvement after myocardial infarction [13,41].”
BackgroundPotential cardiovascular effects of incretin-based therapies
Deacon, C. F., & Marx, N. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.5 · Cited by 19
Abdelaziz, A. I., Mantawy, E. M., Gad, A. M., Fawzy, H. M., & Azab, S. S. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110719 · Cited by 19
Bai, Y., Lian, P., Li, J., Zhang, Z., & Jian, Q. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104645 · Cited by 21
Kalayci, A., Januzzi, J. L., Mitsunami, M., Tanboga, I. H., Karabay, C. Y., & Gibson, C. M. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf037 · Cited by 18
Stoicovy, R. A., Cora, N., Perez, A., Nagliya, D., Calvo, G. D., Lopez, T. B., Weinstein, E., Borges, J. I., Maning, J., & Lymperopoulos, A. (2024) · Inflammation Research · doi:10.1007/s00011-024-01950-0 · Cited by 19
“An inhibitory effect on cardiac NFκB would be consistent with the demonstrated benefits of liraglutide in both acute myocardial infarction (MI) patients [43] and experimental animals post-MI [44] or post-H/R injury [45].”
Anholm, C., Kumarathurai, P., Klit, M. S., Kristiansen, O. P., Nielsen, O. W., Ladelund, S., Madsbad, S., Sajadieh, A., & Haugaard, S. B. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005942 · Cited by 19
Incretin Therapies: Effects Beyond Glycemic Control
Mudaliar, S. R. D., & Henry, R. R. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.05.010 · Cited by 20
Cariou, B. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.04.003 · Cited by 19
“These eneficial effects appear to be mediated by an antiapoptotic ffect on cardiomyocytes [107].”
BackgroundInfluentialCersosimo, A., Salerno, N., Sabatino, J., Scatteia, A., Bisaccia, G., Rosa, S. D., Dellegrottaglie, S., Bucciarelli‐Ducci, C., Torella, D., & Leo, I. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02181-7 · Cited by 17
“It has been also postulated that GLP1-Ra may exert CV beneficial effects by impacting post-MI cardiac remodeling and ischemia-reperfusion (IR) injury [141, Fig.”
Cardiovascular and hemodynamic effects of glucagon-like peptide-1
Goodwill, A. G., Mather, K. J., Conteh, A. M., Sassoon, D., Noblet, J. N., & Tune, J. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9290-z · Cited by 19
“In these studies, wild type mice subjected to 30 minutes of global myocardial ischemia and treated with liraglutide showed enhanced rates of cardiac fractional shortening and significantly increased LV developed pressure during recovery from ischemia [42].”
Multifactorial intervention in Type 2 diabetes: The promise of incretin-based therapies
Giorgino, F., Leonardini, A., Natalicchio, A., & Laviola, L. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03346698 · Cited by 18
Kyhl, K., Lønborg, J., Hartmann, B., Kissow, H., Poulsen, S. S., Ali, H. H. E., Kjær, A., Dela, F., Engstrøm, T., & Treiman, M. (2017) · Peptides · doi:10.1016/j.peptides.2017.04.009 · Cited by 17
Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration
Fakoya, A. O. J., Otohinoyi, D. A., & Yusuf, J. A. (2018) · Stem Cells International · doi:10.1155/2018/3123961 · Cited by 18
“The reported therapeutic effects of liraglutide on the heart include improved cardiac performance [202] and enhanced myocardial blood flow [203], inhibition of CM apoptosis [204], attenuation of infarct size [205], and myocardial signaling pathway activation [206].”
BackgroundChen, J., Xu, S., Wang, L., Zhou, W., Li, P., Deng, N., Tang, Q., Li, Y., Wu, L., Chen, J., et al. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9089 · Cited by 23
“GLP-1 receptor activation preserves cardiac performance by activating multiple pro-survival kinases and modulating cell apoptosis and energy utilization (5-7), and exendin-4 (a long-acting GLP-1 analogue)-mediated GLP-1 receptor activation in models of MI inhibits cardiac remodeling by mitigating oxidative stress-indu…”
BackgroundFujiwara, T., Yoshida, M., Nakamura, T., Sakakura, K., Wada, H., Arao, K., Katayama, T., Funayama, H., Sugawara, Y., Mitsuhashi, T., et al. (2014) · Heart and Vessels · doi:10.1007/s00380-014-0509-4 · Cited by 17
“Ischemia reperfusion injury is reduced, and contraction is improved by GLP-1 [10, 11].”
BackgroundInfluentialPreclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists
Gallwitz, B. (2009) · The Review of Diabetic Studies · doi:10.1900/rds.2009.6.247 · Cited by 17
Monzo, L., Savarese, G., Müllens, W., Abdin, A., Bozkurt, B., Chioncel, O. D., Hadidi, S. E., Gorter, T. M., Inciardi, R. M., Petrie, M. C., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.70082 · Cited by 17
Dipeptidyl peptidase IV and Mortality After an Acute Heart Failure Episode
Lourenço, P., Friões, F., Silva, N., Guimarães, J. T., & Bettencourt, P. (2013) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3182949673 · Cited by 16
Cardiovascular protective properties of incretin-based therapies in type 2 diabetes
Şimşek, S., & de Galan, B. E. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283590b8f · Cited by 16
“Activation of myocardial GLP-1Rs with liraglutide, a GLP-1 analogue, has been shown to have an antiapoptotic effect by reducing caspase-3 cleavage [22].”
BackgroundYin, M., Westenbrink, B. D., Meissner, M., van Gilst, W. H., & de Boer, R. A. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.10.005 · Cited by 16
“[77] ↑ LV function [79–82]”
BackgroundInfluentialСиманенкова, А. В., Минасян, С. М., Каронова, Т. Л., Vlasov, T. D., Тимкина, Н. В., Shpilevaya, O., Константиновна, Х. А., Shimshilashvili, A., Тимофеева, В. А., Samsonov, D., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86132-2 · Cited by 16
Sano, H., Terasaki, J., Murase‐Mishiba, Y., Imagawa, A., & Hanafusa, T. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.12.020 · Cited by 16
Myocardial Protection Against Ischemia-Reperfusion Injury by GLP-1: Molecular Mechanisms
Birnbaum, Y., Ye, Y., & Bajaj, M. (2012) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0095 · Cited by 16
Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin
Borg, M. J., Rayner, C. K., Jones, K. L., Horowitz, M., Xie, C., & Wu, T. (2020) · Pharmaceuticals · doi:10.3390/ph13110410 · Cited by 17
“ventricular contractile function and prolonged survival [76,77].”
Nuamnaichati, N., Parichatikanond, W., & Mangmool, S. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001159 · Cited by 16
Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited
Hansen, J., Brock, B., Bøtker, H. E., GJEDDE, A. H., Rungby, J., & Gejl, M. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9286-8 · Cited by 16
Tu, X.-K., Chen, P., Chen, J., Ding, Y.-H., Chen, Q., & Shi, S. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109603 · Cited by 14
Contractile Effects of Semaglutide in the Human Atrium
Neumann, J., Hadová, K., Klimas, J., Hofmann, B., & Gergs, U. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091139 · Cited by 14
Glucagon‐Like Peptide‐1 Links Ingestion, Homeostasis, and the Heart
Krieger, J., Daniels, D., Lee, S. J., Mastitskaya, S., & Langhans, W. (2024) · Comprehensive physiology · doi:10.1002/cph4.7 · Cited by 15
“Administration of GLP-1R agonists reduces infarct size, improves ventricular function and survival in rodents with experimental myocardial infarction (Basalay et al. 2016; Noyan-Ashraf et al. 2009) (Figure 10C).”
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Puddu, A., Sanguineti, R., Durante, A., Nencioni, A., Mach, F., Montecucco, F., & Viviani, G. L. (2013) · Mediators of Inflammation · doi:10.1155/2013/317120 · Cited by 15
“Interestingly, it has been also reported that Nrf2 is upregulated by analogues of glucagon-like peptide-1 (GLP-1) [20].”
BackgroundWang, C., Zhang, C., Wu, D., Guo, L., Zhao, F., Lv, J., & Fu, L. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105793 · Cited by 14
Cai, H., Zhou, L., Liu, J., Li, Z., & Chen, S. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.09.018 · Cited by 15
Bestepe, F., Fritsche, C. M., Lakhotiya, K., Niosi, C. E., Ghanem, G., Martin, G., Pal‐Ghosh, R., BECKER-GREENE, D. R., Weston, J. A., Hollan, I., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.021 · Cited by 14
Incretin Therapy and Heart Failure
Oyama, J., & Node, K. (2014) · Circulation Journal · doi:10.1253/circj.cj-13-1561 · Cited by 15
“GLP-1(7-36)amide has been widely studied for its role as an active incretin and is referred to as GLP-1, unless otherwise specified.”
InfluentialLebovitz, H. E., & Banerji, M. A. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0022 · Cited by 14
“32 In an in vivo study of a 40-min occlusion of the left anterior descending coronary artery followed by a 2.5-h reperfusion in Landrace pigs, administration of liraglutide (10 l g/kg subcutaneously once daily) for 3 days prior to and during the ischemia re-perfusion had no beneficial effect on…”
InfluentialLiu, R., Li, L., Chen, Y., Yang, M., Liu, H., & Yang, G. (2014) · Annals of Medicine · doi:10.3109/07853890.2014.949837 · Cited by 14
GLP-1 and the cardiovascular system
Kahles, F., Birkenfeld, A. L., & Marx, N. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194748 · Cited by 14
“In addition to vascular protective effects, GLP-1R agonism improves experimental heart failure across several species, including mice (21–32), rats (33–37), pigs (38, 39), and dogs (40, 41) (Figure 2).”
Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
Rutledge, C. A., Enriquez, A., Redding, K., Lopez, M. A., Mullett, S. J., Gelhaus, S. L., Jurczak, M. J., Goetzman, E. S., & Kaufman, B. A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07482-9 · Cited by 13
“GLP-1 receptor agonists have also been shown to improve cardiac outcomes in mouse models of hypertension (17), hypertrophy (4), HFpEF (5,6), and myocardial infarction (18).”
Che, X., Liu, Q., Yu, F., Zhang, L., & Gani, R. (2024) · Computers & Chemical Engineering · doi:10.1016/j.compchemeng.2024.108626 · Cited by 14
Effects of liraglutide and ischemic postconditioning on myocardial salvage after I/R injury in pigs*
Ekström, K., Dalsgaard, M., Iversen, K. K., Pedersen‐Bjergaard, U., Vejlstrup, N., Diemar, S. S., Idorn, M., Thorsteinsson, B., & Engstrøm, T. (2016) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2016.1197417 · Cited by 13
“liraglutide specifically,[4] and in humans.”
Kajiwara, M., Tanaka, A., Kawasaki, T., Nakao, K., Sakamoto, T., Toyoda, S., Inoue, T., Koga, N., & Node, K. (2016) · Journal of Cardiology · doi:10.1016/j.jjcc.2016.10.009 · Cited by 13
Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies
Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 13
Lucci, C., Marongiu, A., Genovese, S., Mazza, M., Cosentino, N., & Marenzi, G. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02862-x · Cited by 12
Umpierrez, G. E., & Meneghini, L. (2013) · Endocrine Practice · doi:10.4158/ep12292.ra · Cited by 12
Dipeptidyl Peptidase-4 Inhibitors and Their Effects on the Cardiovascular System
Solun, B., Marcoviciu, D., & Dicker, D. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0382-2 · Cited by 12
“In this way, GLP-1 receptor agonist’s cardio-protective effect achieved through cytoprotective pathways such as PI3K-Akt pathway activation, leading to improved outcomes and enhanced survival after MI in vivo [33].”
BackgroundSalling, H. K., Döhler, K. D., Engstrøm, T., & Treiman, M. (2012) · Regulatory Peptides · doi:10.1016/j.regpep.2012.06.007 · Cited by 12
“While GLP-1, exendin-4 and liraglutide have all been shown to have an infarct size-limiting action [7,12–18], only GLP-1 and exendin-4 were tested using postconditioning-type, clinically relevant protocols [13,14,18].”
Asleh, R., Sheikh‐Ahmad, M., Briasoulis, Α., & Kushwaha, S. S. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9666-8 · Cited by 12
Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression
Ramadan, N. M., Malek, H. A., Rahman, K. A., El-Kholy, E., Shaalan, D., & Elkashef, W. F. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1162-8196 · Cited by 13
Basal Glucagonlike Peptide 1 Levels and Metabolic Syndrome in Obese Patients
de Luis, D. A., Aller, R., Conde, R., Primo, D., Izaola, O., Castro, M. J., & Sagrado, M. G. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182544f9e · Cited by 12
“However, several experimental studies indicate that they occur independently of effects on glucose metabolism and may involve activation of cyclic guanosine monophosphate/cyclic adenosine monophosphateYdependent pathways.(20) As our data show, obese patients with elevated basal GLP-1 had lower systolic blood pressure…”
BackgroundChen, T., Wo, H.-T., Wu, V. C., Wang, J., Wang, C., Hsieh, I.-C., Kuo, C., & Liu, C. T. (2011) · Immunopharmacology and Immunotoxicology · doi:10.3109/08923973.2011.630398 · Cited by 13
“Use of GLP-1 receptor agonist leads to activation of cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.((5)) A beneficial effect of GLP-1 on vasculature has also been reported in humans with type 2 diabetes and stable coronary RESEARCH ARTICLE”
BackgroundHausenloy, D. J., & Yellon, D. M. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr382 · Cited by 12
Kishimori, T., Kato, T., Wada, A., Tani, A., Yamaji, R., Koike, J., Iwasaki, Y., Matsumoto, T., Yagi, T., & Okada, M. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037510 · Cited by 12
“31 To reduce cardiovascular events, current diabetes guidelines recommend the use of GLP1-RA in patients who are high risk for cardiovascular issues with T2D and recommend the use of SGLT2i in patients with HF and T2D.”
InfluentialThe Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review
Biondi, F., & Madonna, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082705 · Cited by 12
Pathangey, G., Allam, M., Abdelnabi, M. H., Sorajja, D., Fortuin, F. D., Lee, K. S. S., & Bhakta, M. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227910 · Cited by 11
“Post-MI data suggest improved survival and fewer recurrences, particularly in higher BMI or PCI populations, with meta-analyses showing a 14% MI risk reduction [74,80,81].”
Cardiovascular effects of antiobesity drugs: are the new medicines all the same?
Cataldi, M., Cignarelli, A., Giallauria, F., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. A. L. (2020) · International Journal of Obesity Supplements · doi:10.1038/s41367-020-0015-3 · Cited by 11
Nusca, A., Piccirillo, F., Bernardini, F., Filippis, A. D., Coletti, F., Mangiacapra, F., Ricottini, E., Melfi, R., Gallo, P., Cammalleri, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137261 · Cited by 14
Cases, A. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.09.003 · Cited by 16
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
“GLP‑1RAs engage pro‑survival pathways in the mouse heart, improving outcomes following myocardial infarction and enhancing survival (107).”
GLP-1(28-36)amide, a Long Ignored Peptide Revisited
Huang, K., Zhou, B., Ji, K., Peng, A., & Yang, X. (2014) · The Open Biochemistry Journal · doi:10.2174/1874091x01408010107 · Cited by 11
“In a mouse model of myocardial infarction (MI), liraglutide improves cardiac output and reduces infarct size and mortality from cardiac rupture [49].”
BackgroundItoh, A., Irie, J., Tagawa, H., Kusumoto, Y., Kato, M., Kobayashi, N., Tanaka, K., Kikuchi, R., Fujita, M., Nakajima, Y., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.05.013 · Cited by 11
Liraglutide: A once-daily human glucagon-like peptide-1 analogue
Aimaretti, G. (2009) · Journal of Endocrinological Investigation · doi:10.1007/bf03345744 · Cited by 11
Palee, S., Chattipakorn, S. C., & Chattipakorn, N. (2017) · Physiological Research · doi:10.33549/physiolres.933558 · Cited by 11
“Although we did not assess the oxidative stress parameters, previous studies demonstrated that liraglutide activated of PI3K-Akt-eNOS-NO signaling pathway and inhibited of oxidative stress (Inoue et al. 2015, Liu et al. 2016, Noyan-Ashraf et al. 2009).”
BackgroundResultInfluentialGLP-1 receptor agonists show no detrimental effect on sperm quality in mouse models and cell lines
Yin, D., Li, F., Li, X., Wei, T., Shan, C., Zhang, Z., & Wei, R. (2025) · Endocrine · doi:10.1007/s12020-025-04245-4 · Cited by 11
“The dose of 0.2 mg/kg was based on previous studies [10, 11], and showed the caridovascular and renal protection [12, 13].”
InfluentialHaluzík, M., Mráz, M., & Svacina, S. (2014) · Drug Safety · doi:10.1007/s40264-014-0238-8 · Cited by 10
“Preclinical and small clinical studies have shown that GLP1 has numerous beneficial effects on the cardiovascular system including the reduction of blood pressure, the improvement of lipid profile, the amelioration of endothelial dysfunction, and the postulated direct cardioprotection in experimental models of ischemi…”
BackgroundWemelle, E., Marousez, L., Lésage, J., de Lamballerie, M., Knauf, C., & Carneiro, L. (2022) · Antioxidants · doi:10.3390/antiox11061091 · Cited by 10
“It is well established that GLP-1 signaling could activate Nfe2l2 mRNA expression [30,31].”
BackgroundAn Updated Prioritization of Geroscience- Guided FDA-Approved Drugs Repurposed to Target Aging
Leone, M., & Barzilai, N. (2024) · Medical Research Archives · doi:10.18103/mra.v12i2.5138 · Cited by 12
DPP-4 inhibitors and atherosclerosis: The promise
Jialal, I., & Bajaj, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.12.033 · Cited by 10
Pan, X., Chen, J., Wang, T., Zhang, M., Wang, H., & Gao, H. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s215789 · Cited by 11
“As shown in Figure 2A, compare to non-diabetic mice, GLP-1R expression was lower in diabetic mice before and after myocardial IRI.”
BackgroundInfluential
Metadata
- Authors
- Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J.
- Affiliations
- Toronto General Hospital (CA)
- University of Toronto (CA)
- Mouse Imaging Centre, Department of Medical Biophysics, Hospital for Sick Children, Toronto, Ontario, Canada;
- Hospital for Sick Children (CA)
- Mount Sinai Hospital (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-01-16
- Volume
- 58
- Issue
- 4
- Pages
- 975-983
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2661586
- OpenAlex
- W2150913805
- Cited by
- 575
- References
- 47
- Citations by year
- 2026: 17 · 2025: 25 · 2024: 26 · 2023: 20 · 2022: 21 · 2021: 28 · 2020: 25 · 2019: 25 · 2018: 32 · 2017: 36 · 2016: 33 · 2015: 49 · 2014: 41 · 2013: 47 · 2012: 53
- FWCI
- 35.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research (80668)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- liraglutide, GLP-1 receptor agonists, myocardial infarction, cardioprotection, diabetic cardiomyopathy, cardiac rupture, infarct size, Akt/GSK-3β signaling, PPARδ, metformin, caspase-3, cyclic AMP
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Models, Animal, Heart, Cardiomegaly, Humans, Male, Mice, Inbred C57BL, Myocardial Infarction, Organ Size, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.